TSU-16, (Z)-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, is a potent activator of aryl hydrocarbon receptor and increases CYP1A1 and CYP1A2 expression in human hepatocytes

Chemico-Biological Interactions

Volumn 185, Issue 1, 2010, Pages 33-41

  Matsuoka Kawano, Kazuaki ^a,b   Yoshinari, Kouichi ^a   Nagayama, Sekio ^b   Yamazoe, Yasushi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Aryl hydrocarbon receptor; CYP induction; Ligand binding assay; SiRNA; TSU 16

Indexed keywords

3 [(2,4 DIMETHYLPYRROL 5 YL)METHYLIDENYL] 2 INDOLINONE; 3 METHYLCHOLANTHRENE; ANGIOGENESIS INHIBITOR; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; MESSENGER RNA; OMEPRAZOLE; TSU 16; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOSOL; DNA FLANKING REGION; DRUG CLEARANCE; DRUG METABOLISM; DRUG RECEPTOR BINDING; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REPORTER GENE;

ADULT; ANGIOGENESIS INHIBITORS; CELLS, CULTURED; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOSOL; FEMALE; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTES; HUMANS; INDOLES; PROTEIN BINDING; PYRROLES; RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER; YOUNG ADULT;

EID: 77950935687     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.02.014     Document Type: Article

References (32)

1. Verheul H.M., Pinedo H.M. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Clin. Breast Cancer 2000, 1(Suppl. 1):S80-S84.
2. Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994, 367(6463):576-579.
3. Mendel D.B., Laird A.D., Smolich B.D., Blake R.A., Liang C., Hannah A.L., Shaheen R.M., Ellis L.M., Weitman S., Shawver L.K., Cherrington J.M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 2000, 15(1):29-41.
4. Salzberg M., Pless M., Rochlitz C., Ambrus K., Scigalla P., Herrmann R. A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance. Invest. New Drugs 2006, 24(4):299-304.
5. Stopeck A., Sheldon M., Vahedian M., Cropp G., Gosalia R., Hannah A. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin. Cancer Res. 2002, 8(9):2798-2805.
6. Ye C., Sweeny D., Sukbuntherng J., Zhang Q., Tan W., Wong S., Madan A., Ogilvie B., Parkinson A., Antonian L. Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416. Toxicol. In Vitro 2006, 20(2):154-162.
7. Chen S., Operana T., Bonzo J., Nguyen N., Tukey R.H. ERK kinase inhibition stabilizes the aryl hydrocarbon receptor: implications for transcriptional activation and protein degradation. J. Biol. Chem. 2005, 280(6):4350-4359.
8. Green J.F., Thielke K.G., Raffel S. Univalent antigen as elicitor of anaphylactic reactions. J. Immunol. 1970, 104(4):863-873.
9. Li Y., Schellhorn H.E. Rapid kinetic microassay for catalase activity. J. Biomol. Tech. 2007, 18(4):185-187.
10. Daujat M., Peryt B., Lesca P., Fourtanier G., Domergue J., Maurel P. Omeprazole, an inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptor. Biochem. Biophys. Res. Commun. 1992, 188(2):820-825.
11. Kikuchi H., Hossain A., Yoshida H., Kobayashi S. Induction of cytochrome P-450 1A1 by omeprazole in human HepG2 cells is protein tyrosine kinase-dependent and is not inhibited by alpha-naphthoflavone. Arch. Biochem. Biophys. 1998, 358(2):351-358.
12. Ueda R., Iketaki H., Nagata K., Kimura S., Gonzalez F.J., Kusano K., Yoshimura T., Yamazoe Y. A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes. Mol. Pharmacol. 2006, 69(6):1924-1930.
13. Yoshinari K., Ueda R., Kusano K., Yoshimura T., Nagata K., Yamazoe Y. Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochem. Pharmacol. 2008, 76(1):139-145.
14. Pollenz R.S. The mechanism of AH receptor protein down-regulation (degradation) and its impact on AH receptor-mediated gene regulation. Chem. Biol. Interact. 2002, 141(1-2):41-61.
15. Pelkonen O., Turpeinen M., Hakkola J., Honkakoski P., Hukkanen J., Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 2008, 82(10):667-715.
16. Lin J.H. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm. Res. 2006, 23(6):1089-1116.
17. Kikuchi H., Kato H., Mizuno M., Hossain A., Ikawa S., Miyazaki J., Watanabe M. Differences in inducibility of CYP1A1-mRNA by benzimidazole compounds between human and mouse cells: evidences of a human-specific signal transduction pathway for CYP1A1 induction. Arch. Biochem. Biophys. 1996, 334(2):235-240.
18. Shih H., Pickwell G.V., Guenette D.K., Bilir B., Quattrochi L.C. Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Hum. Exp. Toxicol. 1999, 18(2):95-105.
19. Bapiro T.E., Andersson T.B., Otter C., Hasler J.A., Masimirembwa C.M. Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur. J. Clin. Pharmacol. 2002, 58(8):537-542.
20. Fontaine F., Delescluse C., de Sousa G., Lesca P., Rahmani R. Cytochrome 1A1 induction by primaquine in human hepatocytes and HepG2 cells: absence of binding to the aryl hydrocarbon receptor. Biochem. Pharmacol. 1999, 57(3):255-262.
21. Reiners J.J., Lee J.Y., Clift R.E., Dudley D.T., Myrand S.P. PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol. Pharmacol. 1998, 53(3):438-445.
22. Andrieux L., Langouet S., Fautrel A., Ezan F., Krauser J.A., Savouret J.F., Guengerich F.P., Baffet G., Guillouzo A. Aryl hydrocarbon receptor activation and cytochrome P450 1A induction by the mitogen-activated protein kinase inhibitor U0126 in hepatocytes. Mol. Pharmacol. 2004, 65(4):934-943.
23. Dvorak Z., Vrzal R., Henklova P., Jancova P., Anzenbacherova E., Maurel P., Svecova L., Pavek P., Ehrmann J., Havlik R., Bednar P., Lemr K., Ulrichova J. JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytes. Biochem. Pharmacol. 2008, 75(2):580-588.
24. Rost K.L., Brosicke H., Heinemeyer G., Roots I. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology 1994, 20(5):1204-1212.
25. Krusekopf S., Roots I., Hildebrandt A.G., Kleeberg U. Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+-ATPase inhibitors and other xenobiotics. Xenobiotica 2003, 33(2):107-118.
26. Krusekopf S., Kleeberg U., Hildebrandt A.G., Ruckpaul K. Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line. Xenobiotica 1997, 27(1):1-9.
27. Masubuchi N., Hakusui H., Okazaki O. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors. Drug Metab. Dispos. 1997, 25(5):584-589.
28. Zhang Z.Y., Pelletier R.D., Wong Y.N., Sugawara M., Zhao N., Littlefield B.A. Preferential inducibility of CYP1A1 and CYP1A2 by TCDD: differential regulation in primary human hepatocytes versus transformed human cells. Biochem. Biophys. Res. Commun. 2006, 341(2):399-407.
29. Li W., Harper P.A., Tang B.K., Okey A.B. Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. Biochem. Pharmacol. 1998, 56(5):599-612.
30. Santostefano M.J., Ross D.G., Savas U., Jefcoate C.R., Birnbaum L.S. Differential time-course and dose-response relationships of TCDD-induced CYP1B1, CYP1A1, and CYP1A2 proteins in rats. Biochem. Biophys. Res. Commun. 1997, 233(1):20-24.
31. Fontana R.J., Lown K.S., Paine M.F., Fortlage L., Santella R.M., Felton J.S., Knize M.G., Greenberg A., Watkins P.B. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 1999, 117(1):89-98.
32. Fitzgerald E.F., Hwang S.A., Lambert G., Gomez M., Tarbell A. PCB exposure and in vivo CYP1A2 activity among Native Americans. Environ. Health Perspect. 2005, 113(3):272-277.